Annual EBITDA
-$5.61 M
+$781.46 K+12.23%
31 August 2024
Summary:
Lexaria Bioscience annual earnings before interest, taxes, depreciation & amortization is currently -$5.61 million, with the most recent change of +$781.46 thousand (+12.23%) on 31 August 2024. During the last 3 years, it has fallen by -$67.84 thousand (-1.22%). LEXX annual EBITDA is now -1366.58% below its all-time high of $442.70 thousand, reached on 31 October 2012.LEXX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$2.21 M
-$508.86 K-29.87%
31 August 2024
Summary:
Lexaria Bioscience quarterly earnings before interest, taxes, depreciation & amortization is currently -$2.21 million, with the most recent change of -$508.86 thousand (-29.87%) on 31 August 2024. Over the past year, it has dropped by -$1.10 million (-99.26%). LEXX quarterly EBITDA is now -357.22% below its all-time high of $860.20 thousand, reached on 31 October 2007.LEXX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$5.66 M
-$1.17 M-26.02%
31 August 2024
Summary:
Lexaria Bioscience TTM earnings before interest, taxes, depreciation & amortization is currently -$5.66 million, with the most recent change of -$1.17 million (-26.02%) on 31 August 2024. Over the past year, it has increased by +$164.94 thousand (+2.83%). LEXX TTM EBITDA is now -657.76% below its all-time high of $1.02 million, reached on 31 July 2008.LEXX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LEXX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.2% | -99.3% | +2.8% |
| 3 y3 years | -1.2% | -12.0% | +17.1% |
| 5 y5 years | -40.2% | -143.9% | -34.3% |
LEXX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1.2% | +13.9% | -247.4% | +7.6% | -26.0% | +21.1% |
| 5 y | 5 years | -40.2% | +13.9% | -247.4% | +12.8% | -43.6% | +21.1% |
| alltime | all time | -1366.6% | +15.0% | -357.2% | +35.3% | -657.8% | +21.1% |
Lexaria Bioscience EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Aug 2024 | -$5.61 M(-12.2%) | -$2.21 M(+29.9%) | -$5.66 M(+26.0%) |
| May 2024 | - | -$1.70 M(+167.5%) | -$4.49 M(-13.0%) |
| Feb 2024 | - | -$636.80 K(-42.7%) | -$5.17 M(-11.4%) |
| Nov 2023 | - | -$1.11 M(+6.4%) | -$5.83 M(-8.8%) |
| Aug 2023 | -$6.39 M(-2.0%) | -$1.04 M(-56.1%) | -$6.39 M(+5.3%) |
| May 2023 | - | -$2.38 M(+82.9%) | -$6.07 M(-0.3%) |
| Feb 2023 | - | -$1.30 M(-22.3%) | -$6.09 M(-2.0%) |
| Nov 2022 | - | -$1.67 M(+130.8%) | -$6.21 M(-4.7%) |
| Aug 2022 | -$6.52 M(+17.6%) | -$723.80 K(-69.8%) | -$6.52 M(-7.3%) |
| May 2022 | - | -$2.39 M(+68.3%) | -$7.03 M(-2.0%) |
| Feb 2022 | - | -$1.42 M(-28.0%) | -$7.18 M(+5.1%) |
| Nov 2021 | - | -$1.98 M(+59.5%) | -$6.83 M(+23.3%) |
| Aug 2021 | -$5.54 M(+38.4%) | -$1.24 M(-51.2%) | -$5.54 M(+7.1%) |
| May 2021 | - | -$2.54 M(+135.8%) | -$5.17 M(+29.8%) |
| Feb 2021 | - | -$1.08 M(+57.1%) | -$3.99 M(+1.1%) |
| Nov 2020 | - | -$685.20 K(-21.5%) | -$3.94 M(-5.3%) |
| Aug 2020 | -$4.00 M(+0.1%) | -$872.90 K(-35.4%) | -$4.16 M(-2.9%) |
| May 2020 | - | -$1.35 M(+30.5%) | -$4.29 M(+4.4%) |
| Feb 2020 | - | -$1.03 M(+14.0%) | -$4.11 M(-2.6%) |
| Nov 2019 | - | -$907.00 K(-9.0%) | -$4.22 M(+5.4%) |
| Aug 2019 | -$4.00 M(-39.4%) | -$997.00 K(-14.7%) | -$4.00 M(-5.4%) |
| May 2019 | - | -$1.17 M(+2.3%) | -$4.23 M(-34.8%) |
| Feb 2019 | - | -$1.14 M(+65.6%) | -$6.48 M(-3.5%) |
| Nov 2018 | - | -$690.20 K(-43.7%) | -$6.71 M(+1.7%) |
| Aug 2018 | -$6.60 M(+243.3%) | -$1.23 M(-64.2%) | -$6.60 M(+8.3%) |
| May 2018 | - | -$3.42 M(+148.5%) | -$6.09 M(+102.2%) |
| Feb 2018 | - | -$1.38 M(+139.5%) | -$3.01 M(+43.6%) |
| Nov 2017 | - | -$574.80 K(-20.0%) | -$2.10 M(+9.2%) |
| Aug 2017 | -$1.92 M(+50.8%) | -$718.30 K(+110.0%) | -$1.92 M(+25.7%) |
| May 2017 | - | -$342.10 K(-26.1%) | -$1.53 M(+5.5%) |
| Feb 2017 | - | -$462.70 K(+16.0%) | -$1.45 M(+14.9%) |
| Nov 2016 | - | -$398.80 K(+22.5%) | -$1.26 M(-1.0%) |
| Aug 2016 | -$1.27 M(-34.7%) | -$325.50 K(+23.9%) | -$1.27 M(-18.5%) |
| May 2016 | - | -$262.70 K(-4.3%) | -$1.56 M(-13.7%) |
| Feb 2016 | - | -$274.40 K(-33.3%) | -$1.81 M(-9.2%) |
| Nov 2015 | - | -$411.50 K(-33.2%) | -$2.00 M(+2.3%) |
| Aug 2015 | -$1.95 M | -$615.60 K(+20.5%) | -$1.95 M(+7.4%) |
| May 2015 | - | -$511.00 K(+11.4%) | -$1.82 M(+7.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Feb 2015 | - | -$458.60 K(+25.1%) | -$1.69 M(+37.2%) |
| Nov 2014 | - | -$366.50 K(-23.8%) | -$1.23 M(+7.8%) |
| Aug 2014 | -$1.23 M(+7554.7%) | - | - |
| July 2014 | - | -$480.80 K(+24.4%) | -$1.14 M(+91.6%) |
| Apr 2014 | - | -$386.50 K(-3216.9%) | -$597.30 K(+375.2%) |
| Jan 2014 | - | $12.40 K(-104.3%) | -$125.70 K(+680.7%) |
| Oct 2013 | -$16.10 K(-103.6%) | -$289.70 K(-535.6%) | -$16.10 K(-102.9%) |
| July 2013 | - | $66.50 K(-21.9%) | $550.20 K(-29.8%) |
| Apr 2013 | - | $85.10 K(-30.2%) | $783.40 K(+38.7%) |
| Jan 2013 | - | $122.00 K(-55.9%) | $565.00 K(+27.6%) |
| Oct 2012 | $442.70 K(+298.5%) | $276.60 K(-7.7%) | $442.70 K(+23.3%) |
| July 2012 | - | $299.70 K(-324.8%) | $359.10 K(-690.6%) |
| Apr 2012 | - | -$133.30 K(>+9900.0%) | -$60.80 K(-207.4%) |
| Jan 2012 | - | -$300.00(-100.2%) | $56.60 K(-49.1%) |
| Oct 2011 | $111.10 K(-142.2%) | $193.00 K(-260.6%) | $111.10 K(-197.7%) |
| July 2011 | - | -$120.20 K(+656.0%) | -$113.70 K(-242.8%) |
| Apr 2011 | - | -$15.90 K(-129.3%) | $79.60 K(-8060.0%) |
| Jan 2011 | - | $54.20 K(-270.4%) | -$1000.00(-99.6%) |
| Oct 2010 | -$263.00 K(+4.6%) | -$31.80 K(-143.5%) | -$262.90 K(-8.2%) |
| July 2010 | - | $73.10 K(-175.8%) | -$286.30 K(-37.8%) |
| Apr 2010 | - | -$96.50 K(-53.5%) | -$460.50 K(-1.2%) |
| Jan 2010 | - | -$207.70 K(+276.3%) | -$466.10 K(+85.4%) |
| Oct 2009 | -$251.40 K(+534.8%) | -$55.20 K(-45.4%) | -$251.40 K(-22.9%) |
| July 2009 | - | -$101.10 K(-1.0%) | -$326.20 K(+89.1%) |
| Apr 2009 | - | -$102.10 K(-1558.6%) | -$172.50 K(+140.6%) |
| Jan 2009 | - | $7000.00(-105.4%) | -$71.70 K(-384.5%) |
| Oct 2008 | -$39.60 K(-95.6%) | -$130.00 K(-347.1%) | $25.20 K(-97.5%) |
| July 2008 | - | $52.60 K(-4146.2%) | $1.02 M(-667.6%) |
| Apr 2008 | - | -$1300.00(-101.3%) | -$178.90 K(-67.4%) |
| Jan 2008 | - | $103.90 K(-87.9%) | -$548.10 K(-30.2%) |
| Oct 2007 | -$901.80 K(+594.8%) | $860.20 K(-175.3%) | -$784.90 K(-53.0%) |
| July 2007 | - | -$1.14 M(+208.2%) | -$1.67 M(+187.2%) |
| Apr 2007 | - | -$370.50 K(+178.8%) | -$581.90 K(+141.4%) |
| Jan 2007 | - | -$132.90 K(+407.3%) | -$241.10 K(+75.9%) |
| Oct 2006 | -$129.80 K(+269.8%) | -$26.20 K(-49.9%) | -$137.10 K(+23.6%) |
| July 2006 | - | -$52.30 K(+76.1%) | -$110.90 K(+89.2%) |
| Apr 2006 | - | -$29.70 K(+2.8%) | -$58.60 K(+102.8%) |
| Jan 2006 | - | -$28.90 K | -$28.90 K |
| Oct 2005 | -$35.10 K | - | - |
FAQ
- What is Lexaria Bioscience annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Lexaria Bioscience?
- What is Lexaria Bioscience annual EBITDA year-on-year change?
- What is Lexaria Bioscience quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Lexaria Bioscience?
- What is Lexaria Bioscience quarterly EBITDA year-on-year change?
- What is Lexaria Bioscience TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Lexaria Bioscience?
- What is Lexaria Bioscience TTM EBITDA year-on-year change?
What is Lexaria Bioscience annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of LEXX is -$5.61 M
What is the all time high annual EBITDA for Lexaria Bioscience?
Lexaria Bioscience all-time high annual earnings before interest, taxes, depreciation & amortization is $442.70 K
What is Lexaria Bioscience annual EBITDA year-on-year change?
Over the past year, LEXX annual earnings before interest, taxes, depreciation & amortization has changed by +$781.46 K (+12.23%)
What is Lexaria Bioscience quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of LEXX is -$2.21 M
What is the all time high quarterly EBITDA for Lexaria Bioscience?
Lexaria Bioscience all-time high quarterly earnings before interest, taxes, depreciation & amortization is $860.20 K
What is Lexaria Bioscience quarterly EBITDA year-on-year change?
Over the past year, LEXX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$1.10 M (-99.26%)
What is Lexaria Bioscience TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of LEXX is -$5.66 M
What is the all time high TTM EBITDA for Lexaria Bioscience?
Lexaria Bioscience all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.02 M
What is Lexaria Bioscience TTM EBITDA year-on-year change?
Over the past year, LEXX TTM earnings before interest, taxes, depreciation & amortization has changed by +$164.94 K (+2.83%)